Aromatase inhibitors should replace tamoxifen as the first choice for preventing recurrence of breast cancer in postmenopausal women with localized hormone receptor-positive disease, according to this large-scale study.
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.